Yunnan Baiyao Group Overview
- Year Founded
-
1902
- Status
-
Public
- Employees
-
9,286
- Stock Symbol
-
000538
- Investments
-
2
- Share Price
-
$8.46
- (As of Friday Closing)
Yunnan Baiyao Group General Information
Description
Yunnan Baiyao Group Co Ltd is engaged in the manufacturing and marketing of medicines, which include herbal products, daily health products, raw medicine, drug classics, and others.
Contact Information
Website
www.yunnanbaiyao.com.cnCorporate Office
- No. 3686, Yunnan Baiyao Street
- Chenggong District
- Kunming, Yunnan 650500
- China
Corporate Office
- No. 3686, Yunnan Baiyao Street
- Chenggong District
- Kunming, Yunnan 650500
- China
Yunnan Baiyao Group Stock Performance
As of 20-Nov-2026, Yunnan Baiyao Group’s stock price is $8.46. Its current market cap is $15.1B with 1.78B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.46 | $8.43 | $6.81 - $8.49 | $15.1B | 1.78B | 9.1M | $0.42 |
Yunnan Baiyao Group Financials Summary
As of 30-Sep-2026, Yunnan Baiyao Group has a trailing 12-month revenue of $6.21B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,348,526 | 12,657,206 | 12,637,970 | 10,783,078 |
| Revenue | 6,208,004 | 5,727,321 | 5,579,196 | 5,528,192 |
| EBITDA | 867,750 | 880,931 | 813,632 | 691,398 |
| Net Income | 754,237 | 716,626 | 661,897 | 578,636 |
| Total Assets | 8,183,489 | 7,756,311 | 7,248,419 | 7,587,435 |
| Total Debt | 50,172 | 69,693 | 96,516 | 281,648 |
Yunnan Baiyao Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Yunnan Baiyao Group Comparisons
Industry
Financing
Details
Yunnan Baiyao Group Competitors (1)
One of Yunnan Baiyao Group’s competitors is Zhangzhou Pien Tze Huang Pharmaceutical, a Corporation company based in Zhangzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zhangzhou Pien Tze Huang Pharmaceutical | Corporation | Zhangzhou, China |
Yunnan Baiyao Group Patents
Yunnan Baiyao Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228387-A1 | Anti-lrrc15 antibody and use thereof | Pending | 27-Apr-2025 | ||
| WO-2026228386-A1 | Anti-nectin-4 antibody and use thereof | Pending | 27-Apr-2025 | ||
| AU-2022437929-A1 | Antibody molecule against growth and differentiation factor 15 and use thereof | Active | 26-Jan-2022 | ||
| AU-2022437929-B2 | Antibody molecule against growth and differentiation factor 15 and use thereof | Active | 26-Jan-2022 | ||
| EP-4471059-A1 | Antibody molecule against growth and differentiation factor 15 and use thereof | Pending | 26-Jan-2022 | C07K16/22 |
Yunnan Baiyao Group Signals
Yunnan Baiyao Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Yunnan Baiyao Group Investments & Acquisitions (2)
Yunnan Baiyao Group’s most recent deal was a Merger/Acquisition with Juyaotang Pharmaceutical for . The deal was made on 11-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Juyaotang Pharmaceutical | 11-Oct-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Joint Venture (Yunnan Baiyao Group/ Ban Loong Holdings) | 23-Apr-2021 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Yunnan Baiyao Group ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
34.22 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Yunnan Baiyao Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Juyaotang Pharmaceutical | Anguo, China | 2013 |
Yunnan Baiyao Group FAQs
-
When was Yunnan Baiyao Group founded?
Yunnan Baiyao Group was founded in 1902.
-
Where is Yunnan Baiyao Group headquartered?
Yunnan Baiyao Group is headquartered in Kunming, China.
-
What is the size of Yunnan Baiyao Group?
Yunnan Baiyao Group has 9,286 total employees.
-
What industry is Yunnan Baiyao Group in?
Yunnan Baiyao Group’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Yunnan Baiyao Group a private or public company?
Yunnan Baiyao Group is a Public company.
-
What is Yunnan Baiyao Group’s stock symbol?
The ticker symbol for Yunnan Baiyao Group is 000538.
-
What is the current stock price of Yunnan Baiyao Group?
As of 20-Nov-2026 the stock price of Yunnan Baiyao Group is $8.46.
-
What is the current market cap of Yunnan Baiyao Group?
The current market capitalization of Yunnan Baiyao Group is $15.1B.
-
What is Yunnan Baiyao Group’s current revenue?
The trailing twelve month revenue for Yunnan Baiyao Group is $6.21B.
-
Who are Yunnan Baiyao Group’s competitors?
Zhangzhou Pien Tze Huang Pharmaceutical is a competitor of Yunnan Baiyao Group.
-
What is Yunnan Baiyao Group’s annual earnings per share (EPS)?
Yunnan Baiyao Group’s EPS for 12 months was $0.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process